Published in
Elsevier, European Journal of Cancer, 1(48), p. 85-93
DOI: 10.1016/j.ejca.2011.10.014
Links
Tools
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
Journal article published in 2012 by
K. Fizazi,
J. S. De Bono 
,
A. Flechon,
A. Heidenreich,
E. Voog,
N. B. Davis ,
Ming Qi,
R. Bandekar,
J. T. Vermeulen,
M. Cornfeld,
G. R. Hudes
,
A. Flechon,
A. Heidenreich,
E. Voog,
N. B. Davis ,
Ming Qi,
R. Bandekar,
J. T. Vermeulen,
M. Cornfeld,
G. R. Hudes
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 